BioSight
Companies
Prime Medicine, Inc. logo

PRME

NASDAQCAMBRIDGE, MA
Prime Medicine, Inc.

Prime Medicine is a clinical-stage gene editing company developing prime editing therapeutics for rare genetic diseases and oncology. The company's proprietary Prime Editing technology platform is being applied across multiple programs targeting indications where there are significant unmet medical needs, with advancement through preclinical studies and investigational new drug applications.

Price history not yet available for PRME.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar